A clinical trial involving linaclotide was registered as of August 21, 2026. The study, titled "MRI Parameters as Biomarkers in Cystic Fibrosis (FEMPTO)," is listed under identifier NCT07780344. Its phase is designated as not applicable. As of the listed date, the trial status is not yet recruiting, meaning enrollment of participants has not begun. The trial record does not specify a phase classification, consistent with studies that are observational or biomarker focused rather than traditional dose ranging or efficacy trials. No results, outcomes, or findings have been posted for this study at this time. The listing reflects only the trial's registration status and title as provided. Readers should note that a not yet recruiting status indicates the trial has been registered but has not started accepting participants. Further updates would be expected as the trial progresses through recruitment and subsequent phases, if applicable. For additional context on linaclotide, including its approved regulatory status, readers can consult the compound overview.
Linaclotide Featured in New Trial: FEMPTO MRI Biomarker Study
See the full linaclotide overview
Source: https://clinicaltrials.gov/study/NCT07780344